Integrium, LLC Executives to Attend Cell & Gene Meeting on the Mesa

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be attending the Cell & Gene Meeting on the Mesa on October 4-6, 2017 in La Jolla, CA. The annual event brings together top executives in the life sciences industry and guests that are eager to join forces to find solutions for the healthcare field. With a focus in regenerative medicine, the Cell & Gene Meeting on the Mesa highlights the importance of gene therapy and the crucial role it plays in advancing a wide range of therapeutic areas and medicine.

The event provides meeting opportunities by promoting their Partnering Forum and use of an online system to connect guests with industry leaders. The system allows Integrium to collaborate and learn more about the regenerative medicine field, new trends, and potential partnerships that could be available.

Integrium will be available for meetings throughout the event and encourages guests to connect with Mike Loftus, Executive Director of Business Development via the online partnering system: Partnering System. If you have trouble viewing the link, please contact Emily MacHale, Associate Director of Marketing & Research at

To learn more about Integrium’s regenerative medicine experience, please visit us online at: Integrium Expertise.

About Integrium

Founded in 1998 by visionary clinical research thought leaders, Integrium is a full-service Phase I-IV clinical CRO that specializes in a wide range of therapeutic areas. Integrium plays a key role in furthering new medical advancements by helping pharmaceutical companies design and execute clinical studies, ensuring they achieve their objectives on time, on budget, and with expected quality.

Integrium helps Micro Cap, Small Cap, and Privately held Biotechs within the Innovator and Generic space attain clinical data so they can raise the next round of capital. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Regenerative Medicine, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.

Check out our new website!

To learn more about Integrium, please contact:

Emily MacHale
Associate Director of Marketing & Research